Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Heron Therapeutics (HRTX) over the last 4 years, with Q3 2025 value amounting to $4.7 million.

  • Heron Therapeutics' Other Non-Current Liabilities rose 184771.78% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 184771.78%. This contributed to the annual value of $615000.0 for FY2024, which is 15518.67% up from last year.
  • Per Heron Therapeutics' latest filing, its Other Non-Current Liabilities stood at $4.7 million for Q3 2025, which was up 184771.78% from $747000.0 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other Non-Current Liabilities registered a high of $4.7 million during Q3 2025, and its lowest value of $241000.0 during Q1 2022.
  • Its 4-year average for Other Non-Current Liabilities is $625933.3, with a median of $241000.0 in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first changed by 0.0% in 2023, then soared by 184771.78% in 2025.
  • Quarter analysis of 4 years shows Heron Therapeutics' Other Non-Current Liabilities stood at $241000.0 in 2022, then changed by 0.0% to $241000.0 in 2023, then surged by 155.19% to $615000.0 in 2024, then soared by 663.25% to $4.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $4.7 million for Q3 2025, versus $747000.0 for Q2 2025 and $682000.0 for Q1 2025.